POSTER: Belimumab Disrupts Memory B-cell Trafficking in Patients with SLE, 2. (Poster No. The estimated base pay is $154,315 per year. Quick Links Grants Compassionate Use Investigator Sponsored Studies GSK study Register (Clinical Trial Data and Trial Recruitment) Oncohematology You are using an unsupported browser.Some features of this site may not function properly. POSTER: Differentiation of Niraparib and Olaparib Brain Penetration in Healthy Rhesus Macaque Monkeys, 5. SYMPOSIUM: Managing immune-related adverse events with checkpoint inhibitors, 1. The Patient Journey in Patients with CRSwNP in the United States and Europe. 2017;276(1):97-111. Home | GSK US Understanding heterogeneity in patient preferences for maintenance inhaler therapies in asthma. POSTER: Cobolimab with Dostarlimab and Docetaxel in Patients with Advanced Non-small Cell Lung Cancer (NSCLC): COSTAR Lung COSTAR, 2. Ferguson GT, Brown N, Compton C, et al. Patient Profiles in Eosinophilic Granulomatosis With Polyangiitis (EGPA) ? Time without symptoms or toxicity in patients with recurrent ovarian cancer receiving niraparib maintenance treatment versus placebo: A TWiST analysis of the ENGOT OV16/NOVA trial, 2. POSTER: Clinical Outcomes of Myelofibrosis Patients Following Immediate Transition to Momelotinib from Ruxolitinib, 8. OX40 agonists and combination immunotherapy: putting the pedal to the metal. This site is intended for US Healthcare Professionals. The estimated total pay for a Medical Affairs at GSK is $206,808 per year. . Baseline Characteristics in Patients with Eosinophilic Granulomatosis with Polyangiitis in the U.S. Rates of Major Events in Untreated Patients Diagnosed ?With Anemia of CKD in France?? 1. Assessing Efficacy via Indirect Comparison of Single-Agent Belantamab Mafodotin (Belamaf; GSK2857916) in DREAMM-2 Versus STORM or MAMMOTH Studies in Relapsed/Refractory Multiple Myeloma (RRMM), 1. Pavord ID, Fowler A, Kerstjens HA, et al. POSTER: Exploring Alternative Dosing Regimens of Single-agent Belantamab Mafodotin on Safety and Efficacy in Patients with Relapsed or Refractory Multiple Myeloma: DREAMM-14, 6. Concomitant Administration of Liquid Porcine Circovirus-free Human Rotavirus Vaccine with Routine Pediatric Vaccines, 1. Working closely with our employee resource groups, we launched the Accelerating Difference - Ethnic Diversity development program. Use of Mepolizumab among Individuals with Asthma in the U.S. [Poster No. and PD-L1, in platinum-experienced advanced cervical cancer (TiP), 12. Plain Language Summary [HCP USE ONLY]: The Relationship Between Overall Survival (OS), Progression-Free Survival (PFS), and Objective Response Rate (ORR) in Immune Checkpoint Inhibitor Clinical Trials of Head and Neck Squamous Cell Carcinoma (HNSCC): A Systematic Review and Meta-Analysis, 15. Chandler R et al. 1. Bintrafusp alfa is a bifunctional fusion protein composed of the extracellular domain of the human transforming growth factor ? POSTER: DREAMM-9: Phase 3 Study of Belantamab Mafodotin Plus VRd vs VRd Alone in Transplant Ineligible Newly Diagnosed Multiple Myeloma (TI NDMM), 9. P806; Abstract A4295]. Real-World Effectiveness Of Mepolizumab In Patients With Allergic And Non-Allergic Asthma. Learn how to prepare, what will be collected, and how to safely store your medicine until the event at: 1. POSTER: Treatment patterns among metastatic synovial sarcoma patients in the US Oncology Network, 4. Affairs portal to a separate website maintained by PRMT5 is overexpressed in multiple tumor types, including lymphoma and breast, lung, and bladder cancer, and regulates splicing, gene expression, and activation of p53. What we do can transform our patient and shareholder outcomes, and the experience of our people. EU Medical Affairs Lead, Hematology - jobs.gsk.com Analysis of Co-Resistance Among Klebsiella pneumoniae Urine Isolates From Female Outpatients in the United States. Treatment sequencing among asthma patients who were newly treated with long-acting antimuscarinic antagonist (LAMA) in the United States. Faes S, Dormond O. PI3K and AKT: unfaithful partners in cancer. 801; Abstract A7738]. Paclitaxel Versus Placebo + Carboplatin?Paclitaxel in Recurrent or Primary Advanced Endometrial Cancer, 7. GSK ViiV (GSK) Global Medical Affairs Director Durham, NC 30d+ $121K-$193K Per Year (Glassdoor est.) . Dawson M, Stein EM, Huntly BJP, et al. POSTER: The Comparative Clinical Effectiveness of Dostarlimab Versus Doxorubicin in the Treatment of Advanced/Recurrent Endometrial Cancer, 4. 2. Rothnie KJ, Bancroft T, Bogart M, et al. Steinfeld J, Roufosse F, Kahn JE, et al. Herrera-Restrepo O et al. Poster No. POSTER: Subramanian S, et al. pour nous faire part du problme. Medical affairs Jobs | Glassdoor Predicting Improvements in COPD with Clinically Important Improvements in Patient-Reported Outcomes: A Post Hoc Analysis of the EMAX Trial. POSTER: Antitumor activity of dostarlimab by PD-L1 and tumor mutation burden (TMB) in patients (pts) with mismatch repair deficient and proficient (dMMR and MMRp) tumors in the GARNET trial, 2. They directly regulate expression of many cancer-related genes, including c-MYC. Blood. 1466. [Poster No. #ppswgg#myoldmedss#safedisposallz, Real conversations generate impactful change. POSTER: Real-world data on dostarlimab in post-platinum mismatch repair deficient (dMMR)/ microsatellite instability high (MSI-H) advanced/recurrent (A/R) endometrial cancer: descriptive analysis of the French cohort Temporary Authorization of Use (ATU), 8. 1. POSTER: ZENYTH-ESO: Master protocol to assess the safety and recommended Phase 2 dose of next generation NY-ESO-1?specific TCR T-cells in HLA-A*02 patients with synovial sarcoma and myxoid/round cell liposarcoma [Substudy 3, GSK4427296], 12. Time-Dependent Covariate Analysis of Hemoglobin Values ?on Risk of MACE in the ASCEND Trials.